Are you challenged by siloed structures within your Medical Affairs organization? Our latest blog, by Julie Cahill, MD, V.P., Consulting and Medical Director Services, captures the essence and importance of cross-functional integration within Medical Affairs organizations.
Lumanity brings together a diverse collection of expert perspectives to uncover innovative yet pragmatic approaches to address the diverse and complex set of challenges associated with bringing medical advances to patients.
Our host Peg Crowley-Nowick and guest Tamas Suto, Head of Global MA Oncology at Merck KGaA, Darmstadt, Germany, discuss how leading Medical Affairs (MA) organizations have begun to strategically redefine their team’s requisite executional capabilities to enhance and tailor frontline engagement initiatives.
Partnering with an Alliance and aligning your medical strategy can be a daunting task. Zipher’s own Julie Cahill, MD outlines a unique approach for developing a concise medical strategy that drives impact and demonstrates value.
Arsenal Capital Partners, a private equity firm specializing in building healthcare businesses, today announced the acquisition of Zipher Medical Affairs, a leading provider of expert medical affairs strategic consulting services in the United States.
Insights provide the ability to gain a clear, deep, and sometimes unexpected understanding of a complicated problem or situation. In the pharmaceutical arena, insights are external trends that are actionable and have the potential to alter medical strategy
Host Peg Crowley-Nowick, PhD, MBA, Founder & President of Zipher Medical Affairs and Murial Siadak, PAC, spotlight the ever-increasing value and impact of insights on product strategy, positioning, and tactics.
Drs. Crowley-Nowick and Keir set the stage for a successful launch as they consider the key components of a MA Team and their contributions on the road to launch and beyond, from the formation and training of the Medical Science Liaison Team (MSLs) to the early inclusion of Medical Information, to developing best practices for Scientific Communications while also engaging with Patient Advocacy groups as part of the planning process.
Starting from the clinical trials and ending with meeting the regulatory demands across various countries, bringing a product to market successfully has become increasingly difficult. Therefore, it is critical that an overall launch strategy is established and executed.
Looking to learn more about our service offerings?
Thanks for your interest in our recent white paper, Defining the Course and Navigating the Finish Line: Why Life Sciences Companies Need Medical Affairs in Today’s Highly Competitive Pharmaceutical Landscape.